Stockreport

Kiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer

Kiromic BioPharma, Inc.  (KRBP) 
PDF Stabilization of Disease Observed at Six Weeks, Therapy Continues to Be Well Tolerated HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or t [Read more]